Ziccum
Private Company
Total funding raised: $9.2M
Overview
Ziccum is a pre-revenue, public biotech company developing a novel, heat-free drying platform called LaminarPace for biologics and vaccines. The core technology uses mass transfer principles to create stable, particle-engineered dry powders, potentially enabling new administration routes and reducing cold chain dependencies. Despite its innovative platform, the company filed for bankruptcy in January 2025, casting significant uncertainty over its future operations and ability to secure licensing partnerships.
Technology Platform
LaminarPace: An ambient-temperature mass transfer drying system that converts liquid biologics and vaccines into thermostable, particle-engineered dry powders without heat stress.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Ziccum competes with other biotech firms and large pharma internal efforts focused on lyophilization, spray drying, and novel stabilization methods for biologics. Key competitive factors include scalability, cost, particle engineering control, and the ability to preserve complex molecular structures without efficacy loss.